Literature DB >> 24411627

Radiation therapy administration and survival in stage I/II extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

Adam J Olszewski1, Amrita Desai2.   

Abstract

PURPOSE: To determine the factors associated with the use of radiation therapy and associated survival outcomes in early-stage marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). METHODS AND MATERIALS: We extracted data on adult patients with stage I/II MALT lymphoma diagnoses between 1998 and 2010 recorded in the Surveillance, Epidemiology, and End Results (SEER) database. We studied factors associated with radiation therapy administration in a logistic regression model and described the cumulative incidence of lymphoma-related death (LRD) according to receipt of the treatment. The association of radiation therapy with survival was explored in multivariate models with adjustment for immortal time bias.
RESULTS: Of the 7774 identified patients, 36% received radiation therapy as part of the initial course of treatment. Older patients; black or Hispanic men; white, Hispanic, and black women; and socioeconomically disadvantaged and underinsured patients had a significantly lower chance of receiving radiation therapy. Radiation therapy administration was associated with a lower chance of LRD in most sites. In cutaneous, ocular, and salivary MALT lymphomas, the 5-year estimate of LRD after radiation therapy was 0%. The association of radiation therapy with overall survival in different lymphoma sites was heterogeneous, and statistically significant in cutaneous (hazard ratio 0.45, P=.009) and ocular (hazard ratio 0.47, P<.0001) locations after multivariate adjustment.
CONCLUSIONS: Demographic factors are associated with the use of radiation therapy in MALT lymphoma. Clinicians should be sensitive to those disparities because the administration of radiation therapy may be associated with improved survival, particularly in cutaneous and ocular lymphomas.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24411627     DOI: 10.1016/j.ijrobp.2013.11.225

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not?

Authors:  Juan Pablo Alderuccio; Derek Isrow; Isildinha M Reis; Sunil Girish Iyer; Jessica J Meshman; Wei Zhao; Francisco Vega; Jennifer R Chapman; Arnold M Markoe; Izidore S Lossos
Journal:  Blood       Date:  2020-04-09       Impact factor: 22.113

2.  [Clinicopathological features and possible prognostic factors in parotid lymphomas].

Authors:  Q Su; X Peng; C X Zhou; G Y Yu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-02-18

Review 3.  Clinical aspects of malt lymphomas.

Authors:  Christina Kalpadakis; Gerassimos A Pangalis; Theodoros P Vassilakopoulos; Stavroula Kyriakaki; Xanthi Yiakoumis; Sotirios Sachanas; Maria Moschogiannis; Pantelis Tsirkinidis; Penelope Korkolopoulou; Helen A Papadaki; Maria K Angelopoulou
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

4.  The use of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography integrated with computed tomography for accurate staging and surveillance in the case of mucosa-associated lymphoid tissue.

Authors:  Shunqing Zhang; Allen Rossetti-Chung; Sumit Sood; Stephanie Terezakis
Journal:  J Radiol Case Rep       Date:  2021-03-31

Review 5.  The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas.

Authors:  Laahn H Foster; Craig A Portell
Journal:  Curr Treat Options Oncol       Date:  2015-06

6.  Impact of Marital Status on Survival in Patients with Ocular and Periocular Malignancies: A Retrospective Analysis of 3159 Patients from the SEER Database.

Authors:  Asad Loya; Talha Ayaz; Christina Y Weng
Journal:  Clin Ophthalmol       Date:  2020-04-23

7.  Conventional Treatments Cannot Improve Outcomes of Early-Stage Primary Breast Marginal Zone Lymphoma.

Authors:  Hailing Liu; Jing Zhang; Lin Quan; Lei Cao; Yi Miao; Xiaoli Zhao; Haorui Shen; Li Wang; Wei Xu; Jianyong Li; Lei Fan
Journal:  Front Oncol       Date:  2021-04-13       Impact factor: 6.244

8.  Efficacy of low-dose radiotherapy (2 Gy × 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas.

Authors:  Marzia Cerrato; Erika Orlandi; Angelisa Vella; Sara Bartoncini; Giuseppe C Iorio; Diego Bongiovanni; Francesco Capriotti; Carola Boccomini; Francesco Vassallo; Chiara Cavallin; Viola De Luca; Francesca R Giglioli; Umberto Ricardi; Mario Levis
Journal:  Br J Radiol       Date:  2021-06-16       Impact factor: 3.039

9.  The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the United States, part 1: African-American patients.

Authors:  Shearwood McClelland; Brandi R Page; Jerry J Jaboin; Christina H Chapman; Curtiland Deville; Charles R Thomas
Journal:  Adv Radiat Oncol       Date:  2017-08-03

10.  The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the United States-part 3: Hispanic-American patients.

Authors:  Shearwood McClelland; Carmen A Perez
Journal:  Adv Radiat Oncol       Date:  2017-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.